These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17547274)

  • 1. [Sympathomimetics in ADHD. Cardiovascular risks, FDA warns].
    Ostman-Smith I; Dellborg M
    Lakartidningen; 2007 Apr 25-May 1; 104(17):1307. PubMed ID: 17547274
    [No Abstract]   [Full Text] [Related]  

  • 2. ADHD drugs and cardiovascular risk.
    Nissen SE
    N Engl J Med; 2006 Apr; 354(14):1445-8. PubMed ID: 16549404
    [No Abstract]   [Full Text] [Related]  

  • 3. ADHD black box warning: how concerned should we be?
    Cruz R; Kutscher EC
    S D Med; 2007 Feb; 60(2):63, 65. PubMed ID: 17390569
    [No Abstract]   [Full Text] [Related]  

  • 4. ADHD drugs and cardiovascular risk.
    Rappley MD; Moore JW; Dokken D
    N Engl J Med; 2006 May; 354(21):2296-8; author reply 2296-8. PubMed ID: 16729375
    [No Abstract]   [Full Text] [Related]  

  • 5. Facts and public policy: should I keep my child on ADHD drugs?
    Shader RI; Oesterheld JR
    J Clin Psychopharmacol; 2006 Jun; 26(3):223-4. PubMed ID: 16702885
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.
    Hammerness P; Wilens T; Mick E; Spencer T; Doyle R; McCreary M; Becker J; Biederman J
    J Pediatr; 2009 Jul; 155(1):84-9, 89.e1. PubMed ID: 19394037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular effects of methylphenidate.
    Daniels SR
    J Pediatr; 2009 Jul; 155(1):A3. PubMed ID: 19559283
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing.
    Vetter VL; Elia J; Erickson C; Berger S; Blum N; Uzark K; Webb CL; ;
    Circulation; 2008 May; 117(18):2407-23. PubMed ID: 18427125
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder.
    Boellner SW; Pennick M; Fiske K; Lyne A; Shojaei A
    Pharmacotherapy; 2007 Sep; 27(9):1253-62. PubMed ID: 17723079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attention deficit/hyperactivity disorder in adults.
    Moss SB; Nair R; Vallarino A; Wang S
    Prim Care; 2007 Sep; 34(3):445-73, v. PubMed ID: 17868755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The nature of the relationship between attention-deficit/hyperactivity disorder and substance use.
    Wilens TE
    J Clin Psychiatry; 2007; 68 Suppl 11():4-8. PubMed ID: 18307375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adulthood self-reported cardiovascular risk and ADHD medications: results from the 2004-2005 National Epidemiologic Survey on Alcohol and Related Conditions.
    Peyre H; Hoertel N; Hatteea H; Limosin F; Dubuc C; Delorme R
    J Clin Psychiatry; 2014 Feb; 75(2):181-2. PubMed ID: 24602253
    [No Abstract]   [Full Text] [Related]  

  • 15. Sleep characteristics of children and adolescents with attention deficit-hyperactivity disorder.
    Gruber R
    Child Adolesc Psychiatr Clin N Am; 2009 Oct; 18(4):863-76. PubMed ID: 19836693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
    Perrin JM; Friedman RA; Knilans TK; ;
    Pediatrics; 2008 Aug; 122(2):451-3. PubMed ID: 18676566
    [No Abstract]   [Full Text] [Related]  

  • 17. Managing attention-deficit/hyperactivity disorder in primary care: a systematic analysis of roles and challenges.
    Power TJ; Mautone JA; Manz PH; Frye L; Blum NJ
    Pediatrics; 2008 Jan; 121(1):e65-72. PubMed ID: 18166546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylphenidate improves diminished error and feedback sensitivity in ADHD: An evoked heart rate analysis.
    Groen Y; Mulder LJ; Wijers AA; Minderaa RB; Althaus M
    Biol Psychol; 2009 Sep; 82(1):45-53. PubMed ID: 19464338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008.
    American Academy of Pediatrics/American Heart Association
    J Dev Behav Pediatr; 2008 Aug; 29(4):335. PubMed ID: 18698199
    [No Abstract]   [Full Text] [Related]  

  • 20. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
    Winterstein AG; Gerhard T; Shuster J; Zito J; Johnson M; Liu H; Saidi A
    Ann Pharmacother; 2008 Jan; 42(1):24-31. PubMed ID: 18042808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.